Welcome to our dedicated page for VolitionRX news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on VolitionRX stock.
VolitionRx Limited (VNRX) is a U.S.-based epigenetics company at the forefront of developing non-invasive blood tests for early detection and monitoring of life-altering diseases, including various cancers. By leveraging their proprietary Nucleosomics™ platform, VolitionRx is pioneering diagnostic tests that identify and measure nucleosomes in the bloodstream, indicating the presence of disease.
The company's goal is to make these blood tests as commonplace and straightforward as current diabetic and cholesterol tests. VolitionRx operates through subsidiaries, with its primary research and development activities based in Belgium. The company also has offices in the U.S., London, and Singapore, focusing on bringing revolutionary diagnostic products to market across Europe, the U.S., and globally.
VolitionRx's innovative product portfolio includes the Nu.Q® NETs test and the Nu.Q® Vet Cancer Test. The company has recently expanded into veterinary diagnostics with the Nu.Q® Vet Cancer Test, now available in Japan through a partnership with Fujifilm Vet Systems and in the U.S. and Europe through Antech Diagnostics. This expansion aims to provide veterinarians with simple, cost-effective tools for early cancer detection in dogs.
In 2023, VolitionRx achieved several milestones, including significant partnerships and the commercialization of its veterinary products. The company also made strides in its human diagnostics pipeline, with plans to advance its regulatory pathway with the U.S. FDA and large-scale clinical studies scheduled for publication.
VolitionRx remains focused on advancing the science of epigenetics to improve patient outcomes. The company aims to achieve cash flow neutrality by 2025 through a mix of revenue growth, milestone payments from licensing agreements, and cost reduction measures.
For more information, visit www.volitionrx.com, or follow them on Twitter, LinkedIn, and Facebook.
VolitionRx Limited (NYSE AMERICAN: VNRX) has launched its Nu.Q™ Vet Cancer Screening Test, now available for order by veterinarians in the U.S. This low-cost blood test targets older dogs, particularly breeds at higher cancer risk. With an estimated 77 million dogs in the U.S., the test offers potential revenue of $45 per test. It demonstrates 100% specificity, detecting 74% of lymphoma and 89% of hemangiosarcoma. Volition emphasizes the test's role in earlier cancer detection and improved pet care.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced that Dr. Mark Eccleston presented preliminary results on COVID-19 disease monitoring at the MEDICA LABMED FORUM. The studies show elevated circulating nucleosomes in symptomatic COVID-19 patients, leading to a novel patent for disease progression monitoring. Results from ongoing longitudinal studies are anticipated by year-end 2020. The company aims to help in the COVID-19 pandemic and other infections related to NETosis. Severe COVID-19 patients exhibited significantly higher nucleosome levels, indicating potential for using these markers in clinical diagnostics.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced its third quarter 2020 results, highlighting significant advancements in its product launch and clinical programs. The Nu.Q™ Vet Cancer Screening Test is set to launch on November 30, 2020. The company is working with Diagnostic Oncology CRO LLC on a clinical trial for Non-Hodgkin's Lymphoma, expecting FDA submissions 10-12 months into the trial. Financially, cash equivalents rose to approximately $21 million, and a burn rate of $1.6-1.7 million per month is noted. The company anticipates substantial revenue potential from its veterinary diagnostics.
VolitionRx Limited (NYSE AMERICAN: VNRX) has released a report titled A Look to the Future of Cancer Diagnostics, featuring insights from leading veterinary oncology experts. This report highlights the significance of early cancer detection and the introduction of the Nu.Q™ Vet Cancer Screening Test. The test aims to streamline the diagnostic process for canine cancers, including lymphoma and hemangiosarcoma, using a simple blood sample. The report emphasizes the potential benefits of early detection for improving treatment outcomes in pets.
VolitionRx Limited (NYSE AMERICAN: VNRX) will host a conference call on November 13, 2020, at 8:30 a.m. Eastern time to discuss its third quarter 2020 financial and operational results and provide a business update. The call will be led by CEO Cameron Reynolds and CFO David Vanston, covering recent developments, clinical trials, and milestones. A live audio webcast will be available on the investor relations page of Volition's website. The call can also be replayed until November 27, 2020.
On October 21, 2020, VolitionRx Limited (NYSE AMERICAN: VNRX) announced the release of a video from its recent capital markets day event. This event highlighted the upcoming launch of the Nu.Q™ Vet Cancer Screening Test, set for this year, alongside updates on recent developments and clinical trials focused on blood cancer. The presentation featured key insights from executives, including product launch data and clinical trial updates. The video and additional materials are available on Volition's website.
VolitionRx Limited (NYSE AMERICAN: VNRX) is hosting a capital markets day on Oct. 20, 2020, at 8:00 AM ET, featuring a live stream outlining the launch of their Nu.Q™ Vet Cancer Screening Test. Presentations will cover new data and the roll-out plan for this diagnostic tool, expected to launch this year. Key executives will present insights into ongoing clinical trials and product development. The event will be recorded and accessible on Volition's website starting Oct. 21. Volition aims to provide cost-effective blood tests for cancer diagnosis in humans and animals.
VolitionRx Limited (NYSE AMERICAN: VNRX) announces positive data on the Nu.Q™ Vet Cancer Screening Test for Lymphoma and Hemangiosarcoma. The test, expected to launch soon, shows high sensitivity (AUC 87.3%) and specificity (AUC 97.6%) in detecting these cancers in dogs. Cancer is the leading cause of death among dogs over two years in the U.S., with Lymphoma and Hemangiosarcoma accounting for one-third of cases. The objective is to enhance early diagnosis, thereby improving treatment outcomes and quality of life for dogs.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced details for its Capital Markets Day on October 20, 2020, at 8:00 a.m. ET. The event will focus on the launch and commercial rollout of the Nu.Q™ Vet Cancer Screening Test and provide updates on ongoing clinical trials. Presentations will be made by key executives including Cameron Reynolds, Dr. Heather Wilson-Robles, and Dr. Jason Terrell. Registration for the live event is available here. A recording will be available on Volition's website on October 21.
VolitionRx Limited (NYSE AMERICAN: VNRX) will showcase two abstracts for its Nu.Q™ Vet Cancer Screening Test at the 2020 Veterinary Cancer Society (VCS) Virtual Annual Conference from October 15-17. The first abstract on dogs with lymphoma will be presented on October 16 at 1:30 p.m. ET, while the second on dogs with hemangiosarcoma will be on October 17 at 11:15 a.m. ET. Volition will release more details on October 16, and the abstracts will be available on their website starting October 19.
FAQ
What is the current stock price of VolitionRX (VNRX)?
What is the market cap of VolitionRX (VNRX)?
What does VolitionRx Limited do?
Where is VolitionRx Limited based?
What is the Nu.Q® Vet Cancer Test?
What are VolitionRx's recent achievements?
What is the Nucleosomics™ platform?
How is VolitionRx planning to achieve cash flow neutrality by 2025?
How can I get more information about VolitionRx?
What diseases does VolitionRx target with its tests?
What is the significance of VolitionRx's partnership with Fujifilm Vet Systems?
What upcoming milestones does VolitionRx expect?
